Zura Bio to Present Tibulizumab Data on Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

Zura Bio Limited, a clinical-stage immunology company listed on Nasdaq under the ticker ZURA, is advancing its innovative research on dual-pathway antibodies for treating autoimmune and inflammatory diseases. The company recently announced that it will share findings from its tibulizumab (ZB-106) program at the European Congress of Rheumatology (EULAR) 2024, taking place from June 12-15 in Vienna.

The tibulizumab program focuses on a dual-pathway antibody aimed at inhibiting both IL-17A and B-cell Activating Factor (BAFF). This unique approach may offer substantial therapeutic potential in tackling autoimmune diseases like Sjogren's syndrome and rheumatoid arthritis (RA). Chief Scientific Officer Michael Howell, Ph.D., expressed enthusiasm about the upcoming presentation, emphasizing the importance of exploring dual-pathway inhibition to broaden ZB-106’s application across various autoimmune conditions.

Zura Bio will present two sets of data at EULAR 2024. The first set of results, detailed in Poster 0373, will be shared on June 14. This study examines the pharmacokinetics and pharmacodynamics of the dual-pathway antibody in patients with Sjogren’s syndrome. The poster session will take place from 15:27 to 15:33 CEST (9:27 to 9:33 ET). Additionally, the company will discuss findings from a study on resolving inflammation in a mouse model of arthritis through dual antagonism of BAFF and IL-17. This abstract has also been accepted for publication.

Zura Bio is engaged in the development of three primary assets: tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880). All three have completed Phase 1/1b clinical trials and are poised to enter Phase 2. The company aims to demonstrate the efficacy, safety, and dosing convenience of these assets in treating autoimmune and inflammatory diseases, such as systemic sclerosis and other conditions with unmet medical needs.

Importantly, the novel dual-pathway antibody targeting IL-17A and BAFF is expected to progress into Phase 2 development for systemic sclerosis by the fourth quarter of 2024 and for hidradenitis suppurativa by the second quarter of 2025. This forward momentum underscores Zura Bio’s commitment to advancing therapeutic options for patients suffering from debilitating autoimmune conditions.

In summary, Zura Bio’s upcoming presentations at EULAR 2024 signify a crucial step in the clinical validation of their dual-pathway antibody approach. By targeting both IL-17A and BAFF, Zura Bio hopes to offer new, effective treatments for autoimmune diseases, demonstrating the expansive potential of their therapeutic portfolio. The forthcoming data presentations are eagerly anticipated, offering insights that could shape future therapeutic strategies and improve patient outcomes in these challenging disease areas.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!